AKRO Akero Therapeutics

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 12:00 p.m. GMT.

A live webcast of the Company presentation will be available through the investor relations section of the Company's website at . Following the live webcast, an archived replay will be available on the Company's website.

About Akero Therapeutics

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akero's lead product candidate, EFX, is currently being evaluated in three ongoing Phase 3 clinical trials in patients with pre-cirrhotic MASH (F2-F3) or compensated cirrhosis (F4) due to MASH: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes. The SYNCHRONY program builds on the results of two Phase 2b clinical trials, the completed HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the ongoing SYMMETRY study in patients with compensated cirrhosis (F4) due to MASH, in which more than 300 patients have been treated for up to 96 weeks. Akero is headquartered in South San Francisco. Visit us at and follow us on  and  for more information.

Investor Contact:

Christina Tartaglia

Precision AQ

212.362.1200

Media Contact:

Peg Rusconi

617.910.6217



EN
13/11/2024

Underlying

AKROAkero Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Akero Therapeutics

 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMON...

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced publicatio...

August 14, 2025 1 EN
 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics Reports Second Quarter 2025 Financial Results and P...

Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant reversal of compensated cirrhosis (F4) due to MASH and corroborating the anti-fibrotic activity of EFX seen in patients with pre-cirrhotic (F2-F3) MASH Cash, cash equivalents and short and long-term marketable securities of $1,086.2 million at June 30, 2025 SOUTH SAN FRANCISCO, Calif., Aug. ...

August 8, 2025 1 EN
 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global ...

Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025, at 2:40 p.m. E.T. A live webcast of the Company presentation will be available through the investor relations section of...

June 3, 2025 1 EN
 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics to Present at the Jefferies Global Healthcare Confe...

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 8:45 a.m. P.T. A live webcast of the Company presentation will be available through the investor relations section of the Company's website at . Foll...

May 28, 2025 1 EN
 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics Reports First Quarter 2025 Financial Results and Pr...

Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatment with efruxifermin (EFX) Presented two oral presentations and a poster presentation highlighting the latest data and new analyses from 96-week SYMMETRY and HARMONY clinical studies at EASL Congress 2025 SYMMETRY study results published in New England Journal of Medicine Raised $402.5 million in gross proceeds in a follow-on public offering...

May 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch